Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710403 | 1.00 | ALDH1A1 (0.38) | ALDH1A1PKMSCN9APOLBGAA | |
| SCHEMBL3596666 | 1.00 | ALDH1A1 (0.38) | ALDH1A1PKMSCN9APOLBGAA | |
| SCHEMBL3717160 | 0.91 | RBP4 (0.36) | ALDH1A1POLBLMNARAB9A | |
| SCHEMBL12503814 | 0.91 | RBP4 (0.36) | ALDH1A1POLBLMNARAB9A | |
| SCHEMBL18641574 | 0.91 | RBP4 (0.36) | ALDH1A1POLBLMNARAB9A | |
| SCHEMBL31637322 | 0.88 | CYP4F2 (0.42) | ALDH1A1PKMSCN9APOLBGAA | |
| SCHEMBL22207519 | 0.87 | ALDH1A1 (0.38) | ALDH1A1PKMSCN9APOLBGAA | |
| SCHEMBL22207520 | 0.87 | ALDH1A1 (0.38) | ALDH1A1PKMSCN9APOLBGAA | |
| SCHEMBL27035490 | 0.87 | SCN9A (0.42) | ALDH1A1PKMSCN9APOLBGAA | |
| SCHEMBL1710907 | 0.85 | ALDH1A1 (0.37) | ALDH1A1PKMPOLBGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558981-B1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| EP-3349580-A1 | HEPATITIS B CORE PROTEIN MODULATORS | Assembly Biosciences, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017048950-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| WO-2010100144-A1 | FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
| EP-2205559-A1 | RENIN INHIBITORS | Cadila Healthcare Limited (IN) | 2010-07-14 | — | — | EP | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009087649-A1 | RENIN INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2009-07-16 | — | — | WO | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | ALDH1A1 3113/4885PKM 2728/4885SCN9A 51/4885 |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PKD2, QPCT, CCNT2 | ALDH1A1 838/4885PKM 426/4885SCN9A 2778/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | ALDH1A1 3113/4885PKM 2728/4885SCN9A 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.